Our CEO Nicki Thompson has been selected as a finalist in two categories for this year’s European Lifestars Awards: 🏆 Women-Led Business of the Year 🏆 CEO of the Year Full finalist roster: informaconnect.com/european-lif... #lifestarsawards
TRIMTECH Therapeutics
@trimtechtx.bsky.social
Our therapeutic approach is based on pioneering research into TRIM21, an underexploited but widely expressed ubiquitin ligase, that can be directed to treat protein aggregation disorders and bring therapeutic benefits.
CEO Nicki Thompson will be in Boston on 9-10 September for the Oncology & Immunology Innovation Partnering & Licensing Summit. Nicki will join a panel discussing strategies for navigating BD engagements at the seed stage. Get in touch to schedule a meeting: trimtechtherapeutics.com/contact/
CEO Nicki Thompson will be in Oxford for the annual translational research conference “From the Laboratory to the Clinic: Complex Pathogenesis of Disease”. See below for details of her talk ⬇️
Missed our CEO's presentation at the Accelerating Bio-Innovation (ABI) Conference earlier this year? The recording of her talk, "Expanding the Degrader Toolbox for Neuro Applications", is now available to watch on our website: shorturl.at/2HsUE
Starting this Sunday, our team will be at #AAIC26 in London. TRIMTECH is looking forward to a week of scientific sessions, presentations, and networking at the largest international conference dedicated to dementia science. Schedule a meeting 📩 trimtechtherapeutics.com/contact/
Delighted to announce increasing our total seed round to $47M, with an additional $14M investment to support further development of our targeted protein degrader portfolio. Read more: shorturl.at/DfaXn
On Thursday 25 June, Andrea Testa and Dean Clift will be in Maine presenting at the Gordon Research Conference on Induced Proximity Modalities and Therapeutics. See below for more details ⬇️
This Pride Month, and especially with #CambridgePride this weekend, we at TRIMTECH Therapeutics are proud to stand with the LGBTQ+ community.
On June 10th, Co-Founder and Head of Research Damian Crowther will be at the Oxford Science Park for the Creative Disruption Forum on the Future of Neuro Therapeutics and Innovations. See below for session details ⬇️
CEO Nicki Thompson will join ‘The 2026 Biotech Playbook’ panel at One Nucleus' BioBeat event on Thursday 14th May.
We’re delighted that TRIMTECH Therapeutics won 'Start-Up of the Year' at the 2026 Cambridge Independent Science & Technology Awards! Huge thanks to our team and supporters for helping drive our mission forward. Read more: lnkd.in/dJmmd_6S
Our Co-Founder and Head of Research Damian Crowther will be presenting at Magdalene College for Dementia Research Day on Tuesday. See below for details ⬇️
Our CEO Nicki Thompson will be joining the "Partnering with Big Pharma" panel at AngloNordic Life Science Conference XXII in London on Thursday. Reach out if you’d like to meet 📩 trimtechtherapeutics.com/contact/
Our CEO Nicki Thompson is presenting at the Accelerating Bio-Innovation (ABI) Conference in Cambridge next week (20–22 April). Get in touch if you're attending 📩 trimtechtherapeutics.com/contact/
We’re delighted to be shortlisted for this year’s Cambridge Independent Science & Technology Awards, in the 'Start-up of the Year' category. Congratulations to all finalists – we’re looking forward to joining everyone at Hinxton Hall on 7th May for the awards ceremony! More: shorturl.at/QCEKK
This week Damian and Jennie will be attending AD/PD 2026 in Copenhagen for the international conference on Alzheimer's and Parkinson's diseases and related neurological disorders. Stop by our poster presentations to learn more about TRIMTECH’s scientific approach ⬇️
Our Co-Founder and Head of Research Damian Crowther will be presenting at the 6th Annual TPD & Induced Proximity Summit Europe. Schedule a meeting 📩 trimtechtherapeutics.com/contact/
Our CEO, Nicki Thompson, will be in Zurich on 3rd March for the Sachs European Neuroscience Innovation Forum, part of the Sachs Spring Life Sciences Week. Nicki will join the Alzheimer's Disease & Dementia Panel (9:40 AM CET) to discuss the latest progress in drug development.
Our Associate Director, Jennie Gold, will be presenting at the CDD European Life Science Community Meeting. Catch her presentation in the afternoon to learn more about our approach to combat neurodegenerative diseases ⬇️
Meet our Co-founder and Chief Scientific Adviser Dr Leo James, FRS, and learn how his discovery of TRIM21 underpins TRIMTECH’s approach to developing small molecule targeted protein degraders: trimtechtherapeutics.com/meet-the-tea...
Today is the International Day of Women and Girls in Science, observed each year on February 11. At TRIMTECH, we’re proud that our team includes so many talented women scientists at all levels of the organisation whose expertise, dedication, and impact drive our work forward every day.
We have been shortlisted for the One Nucleus Awards 2026, in the ‘Best Therapeutic R&D Programme of the Year’ category! Visit our website to learn more about our work: trimtechtherapeutics.com/science/
Join TRIMTECH Scientist, Jonathan Benn, at the next Cambridge New Therapeutics Forum and learn more about our aggregate-selective targeted protein degrader programme, offering a small molecule approach to combat neurodegenerative diseases. Register here: www.eventbrite.co.uk/e/advances-i...
JPM Healthcare Conference Week 2026 is well underway in San Francisco! Our CEO Nicki Thompson presented at the Cambridge x London Life Sciences Showcase, part of RESI JPM Healthcare Week 2026.
Happy New Year! We’re kicking off 2026 in San Francisco at Sachs’ 9th Annual Neuroscience Innovation Forum and JPM Healthcare Conference Week. Schedule a meeting 📩 trimtechtherapeutics.com/contact/
From all of us at TRIMTECH, happy holidays! 🎄 We’re incredibly proud of what our team has achieved and look forward to another exciting year ahead!
Delighted to welcome Alison Lawton as Chair of our Board. With 35+ years in global biotech and pharma, she brings deep development, operational and leadership experience to support TRIMTECH’s next stage of growth: shorturl.at/xXXbC
Our academic co-founders have published in Nature Communications - detailing the science behind TRIMTECH’s TRIMTAC® degraders. Congrats to Will, Leo, Dean, Jonathan, and all collaborators advancing state-selective protein degradation: www.nature.com/articles/s41...
We’re absolutely delighted to have been awarded ‘Seed Raise of the Year’ at last night’s LSX European Lifestars Awards!
Our team will be in London during Jefferies Global Healthcare Conference Week, kicking off discussions across the global healthcare sector as part of London Life Sciences Week!